Bruker Corporation
NASDAQ•BRKR
CEO: Dr. Frank H. Laukien Ph.D.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2000-08-04
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Contact Information
Market Cap
$4.99B
P/E (TTM)
-579.0
25.9
Dividend Yield
0.6%
52W High
$56.22
52W Low
$28.53
52W Range
Rank30Top 19.5%
5.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$977.20M+0.00%
4-Quarter Trend
EPS
$0.10+0.00%
4-Quarter Trend
FCF
$207.20M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Grows Modestly GAAP Revenue reached $3.44B USD in 2025, showing a 2.1% increase over prior year results despite market softness.
Backlog Shows Strong Increase Remaining Performance Obligations grew to $2.57B USD by year-end 2025, up significantly from $2.09B USD in 2024.
Non-GAAP Margin Pressure Non-GAAP Gross Profit Margin declined to 49.8% in 2025 from 51.6% due to tariffs and foreign exchange headwinds.
Risk Factors
Supply Chain Cost Pressures Component shortages and new U.S. tariffs increased costs, potentially harming revenue and operating results going forward.
Global Economic Geopolitical Risks Adverse global conditions, inflation, and geopolitical tensions negatively affect operations, liquidity, and customer spending forecasts.
Reliance on Government Funding Material revenue derived from U.S. academic customers reliant on NIH/NSF funding; funding delays adversely affect sales growth.
Outlook
Cost Savings Initiative Launched Announced plan to reduce annualized costs by $100M to $120M by end of 2026 to improve operating margins company-wide.
Focus on Recurring Revenue Continued focus on enhancing customer relationships and driving recurring revenue through aftermarket and connected services offerings.
Integrating Recent Acquisitions Focus remains on integrating 2024 and 2025 acquisitions to realize expected synergies and expand technological capabilities.
Peer Comparison
Revenue (TTM)
$5.10B
$3.44B
$2.96B
Gross Margin (Latest Quarter)
89.8%
83.8%
80.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| PCVX | $8.00B | -9.9 | -25.9% | 7.5% |
| KRYS | $7.31B | 35.3 | 18.7% | 0.7% |
| BLCO | $5.84B | -16.2 | -5.6% | 38.3% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
6.8%
Steady Growth
4Q Net Income CAGR
14.3%
Profitability Improving
Cash Flow Stability
50%
Cash Flow Needs Attention
Deep Research
Next earnings:May 5, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data